Sunshine Cash And Short Term Investments from 2010 to 2024
| SBFM Stock | USD 3.04 0.60 24.59% |
Cash And Short Term Investments | First Reported 2007-09-30 | Previous Quarter 11.5 M | Current Value 12.2 M | Quarterly Volatility 9 M |
Check Sunshine Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sunshine Biopharma's main balance sheet or income statement drivers, such as Interest Expense of 148.9 K, Other Operating Expenses of 30.3 M or Total Operating Expenses of 13.8 M, as well as many indicators such as Price To Sales Ratio of 0.26, Dividend Yield of 0.0 or PTB Ratio of 0.3. Sunshine financial statements analysis is a perfect complement when working with Sunshine Biopharma Valuation or Volatility modules.
Sunshine | Cash And Short Term Investments |
Latest Sunshine Biopharma's Cash And Short Term Investments Growth Pattern
Below is the plot of the Cash And Short Term Investments of Sunshine Biopharma over the last few years. Short Term Investments is an account in the current assets section of Sunshine Biopharma balance sheet. This account contains Sunshine Biopharma investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Sunshine Biopharma fairly quickly. It is the sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash. Sunshine Biopharma's Cash And Short Term Investments historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sunshine Biopharma's overall financial position and show how it may be relating to other accounts over time.
| Cash And Short Term Investments | 10 Years Trend |
|
Cash And Short Term Investments |
| Timeline |
Sunshine Cash And Short Term Investments Regression Statistics
| Arithmetic Mean | 3,934,346 | |
| Geometric Mean | 292,249 | |
| Coefficient Of Variation | 193.04 | |
| Mean Deviation | 5,789,695 | |
| Median | 115,216 | |
| Standard Deviation | 7,594,801 | |
| Sample Variance | 57.7T | |
| Range | 21.8M | |
| R-Value | 0.71 | |
| Mean Square Error | 31.1T | |
| R-Squared | 0.50 | |
| Significance | 0 | |
| Slope | 1,200,485 | |
| Total Sum of Squares | 807.5T |
Sunshine Cash And Short Term Investments History
About Sunshine Biopharma Financial Statements
Sunshine Biopharma investors utilize fundamental indicators, such as Cash And Short Term Investments, to predict how Sunshine Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Cash And Short Term Investments | 16.3 M | 17.1 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Sunshine Biopharma Correlation against competitors. To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sunshine Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (127.90) | Revenue Per Share 197.42 | Quarterly Revenue Growth 0.416 | Return On Assets (0.11) | Return On Equity (0.18) |
The market value of Sunshine Biopharma is measured differently than its book value, which is the value of Sunshine that is recorded on the company's balance sheet. Investors also form their own opinion of Sunshine Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sunshine Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sunshine Biopharma's market value can be influenced by many factors that don't directly affect Sunshine Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sunshine Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sunshine Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.